Toggle Nav
mobile icon
My Cart
Close
  • Menu
  • Setting

Bcr-Abl

Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).

Items 1-10 of 16

Page
per page
  1. Nilotinib(AMN-107)
    A8232 Nilotinib(AMN-107)
     1 Citation
    Target: Bcr-Abl
    Summary: Bcr-Abl kinase inhibitor,selective
      ≥26.5 mg/mL
  2. Bosutinib (SKI-606)
    A2149 Bosutinib (SKI-606)
     1 Citation
    Target: Bcr-Abl|Src
    Summary: Potent Abl/Src kinases
      ≥26.5 mg/mL
  3. Imatinib Mesylate (STI571)
    A1805 Imatinib Mesylate (STI571)
    Target: PDGFR|c-Kit|Bcr-Abl
    Summary: Abl/c-kit/PDGFR inhibitor
      ≥29.5 mg/mL
  4. Saracatinib (AZD0530)
    A2133 Saracatinib (AZD0530)
     3 Citation
    Target: Src
    Summary: Src/Abl inhibitor,potent and selective
      ≥27.1 mg/mL
  5. Ponatinib (AP24534)
    A5467 Ponatinib (AP24534)
     1 Citation
    Target: VEGFR|PDGFR|Bcr-Abl|FGFR|Src
    Summary: pan-BCR-ABL inhibitor,multi-kinase inhibitor
      ≥53.3 mg/mL
  6. GNF 2
    A8603 GNF 2
    Summary: Bcr-Abl inhibitor
      insoluble in H2O; ≥18.7 mg/mL
  7. GNF 5
    A8604 GNF 5
    Target: Bcr-Abl
    Summary: Bcr-Abl inhibitor
  8. 1-Naphthyl PP1
    A8605 1-Naphthyl PP1
    Summary: Src family kinases inhibitor
      ≥25.32 mg/mL
  9. PD 180970
    A8606 PD 180970
    Summary: P210bcr/abl tyrosine kinase inhibitor
      <21.46 mg/mL
  10. PPY A
    A8607 PPY A
    Target: Abl kinases
    Summary: Abl kinases inhibitor
      <37.24 mg/mL

Items 1-10 of 16

Page
per page